Group 1 - The core point of the news is that Sinovac Biotech (科兴制药) announced a reduction in shareholding by its controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. (科益医药), and its concerted actor, Deng Xueqin, which resulted in a decrease in their combined shareholding from 66.32% to 65.00% [1][2] - The reduction in shareholding was due to the implementation of a previously disclosed share reduction plan and the dilution of shares resulting from the 2022 restricted stock incentive plan [1][2] - The total number of shares held by Keyi Pharmaceutical and Deng Xueqin decreased from 131,778,347 shares to 129,767,472 shares, representing a reduction of 2,010,875 shares, or 1.32% of the total share capital [1][2] Group 2 - The equity change will not lead to a change in the controlling shareholder or actual controller of Sinovac Biotech [2] - Sinovac Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 14, 2020, with an initial public offering (IPO) of 49.6753 million shares at a price of 22.33 yuan per share [2] - The total amount raised from the IPO was 1.109 billion yuan, with a net amount of 999.5 million yuan, which was 710 million yuan less than the originally planned amount of 1.705 billion yuan [2][3]

Core Viewpoint - Beijing Yitang Semiconductor Technology Co., Ltd. has received approval for its initial public offering (IPO) of A-shares on the Sci-Tech Innovation Board, with the underwriting led by Guotai Junan Securities and China International Capital Corporation [1][2]. Group 1: Issuance Details - The total number of shares for this issuance is set at 29,556,000 shares, with an initial strategic placement of 8,866,800 shares, accounting for 30% of the total issuance [2]. - The final strategic placement amount is 8,055,906.68 shares, which is 27.26% of the total issuance, with the difference of 810,893.2 shares being allocated to offline issuance [2]. - The issuance price is set at RMB 8.45 per share, with 6,287,850 shares being initially issued on June 27, 2025 [2]. Group 2: Subscription and Allocation - The initial effective subscription multiple for online issuance was 2,916.13 times, leading to the activation of a mechanism to adjust the allocation between offline and online subscriptions [3]. - After the adjustment, the final allocation for offline issuance is 15,212,243.2 shares (70.75% of the adjusted total), while online issuance is 6,287,850 shares (29.25% of the adjusted total) [3]. - The final online issuance success rate is 0.05211051% [3]. Group 3: Payment Obligations - Investors are required to fulfill their payment obligations by July 1, 2025, with specific instructions for both offline and online investors regarding the payment process [4][5]. - If the total number of shares subscribed by offline and online investors does not meet 70% of the adjusted total, the issuance will be suspended [5][6]. Group 4: Strategic Placement Results - The strategic placement has concluded successfully, with all participating investors fulfilling their commitments [8]. - The results of the strategic placement are documented in a special verification report and a legal opinion letter [8]. Group 5: Lottery and Allocation Results - The lottery for online issuance was conducted on June 30, 2025, with a total of 125,757 winning numbers, each allowing the purchase of 500 shares [10]. - The offline issuance saw a total of 35,625,720 shares in effective subscriptions, confirming compliance with the issuance announcement [11].

Group 1 - The Shenzhen Stock Exchange accepted the application for the initial public offering (IPO) of Kaiyuan Securities on March 2, 2023, but later decided to terminate the review process after the sponsor withdrew the application [2][3]. - Kaiyuan Securities is a comprehensive brokerage firm with multiple business lines, including securities brokerage, investment consulting, financial advisory, underwriting, proprietary trading, fund sales, asset management, margin financing, and financial product distribution [2]. - The company planned to issue up to 1,153.44 million shares, accounting for no more than 20% of the total share capital post-issue, with the aim to raise 4 billion yuan for capital replenishment and operational funding [3]. Group 2 - The sponsor for the IPO was Minsheng Securities Co., Ltd., now renamed Guolian Minsheng Securities Co., Ltd., with representatives Du Huimin and Jiang Lixing [5].

北京屹唐半导体科技股份有限公司 首次公开发行股票并在科创板上市 网上发行申购情况及中签率公告 保荐人（联席主承销商）：国泰海通证券股份有限公司 联席主承销商：中国国际金融股份有限公司 特别提示 北京屹唐半导体科技股份有限公司（以下简称"发行人"或"屹唐股份"） 首次公开发行人民币普通股（A 股）并在科创板上市（以下简称"本次发行"） 的申请已经上海证券交易所（以下简称"上交所"）科创板上市委员会审议通过， 并已经中国证券监督管理委员会同意注册（证监许可〔2025〕467 号）。 导体科技股份有限公司首次公开发行股票并在科创板上市网下初步配售结果及 网上中签结果公告》（以下简称"《网下初步配售结果及网上中签结果公告》"）， 于 2025 年 7 月 1 日（T+2 日）16:00 前，按最终确定的发行价格与获配数量，及 时足额缴纳新股认购资金。 网下投资者如同日获配多只新股，请务必按每只新股分别缴款。同日获配 多只新股的情况，如只汇一笔总计金额，合并缴款将会造成入账失败，由此产 生的后果由投资者自行承担。 网上投资者申购新股中签后，应根据《网下初步配售结果及网上中签结果公 告》履行资金交收义务，确保其资金账户在 ...

北京屹唐半导体科技股份有限公司 首次公开发行股票并在科创板上市 网上路演公告 保荐人（联席主承销商）：国泰海通证券股份有限公司 联席主承销商：中国国际金融股份有限公司 北京屹唐半导体科技股份有限公司（以下简称"发行人"） 首次公开发行人 民币普通股（A 股）并在科创板上市（以下简称"本次发行"）的申请已经上海证 券交易所科创板上市委员会审议通过，并已经中国证券监督管理委员会同意注册 （证监许可〔2025〕467 号）。 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人（联席主承销 商）"）担任本次发行的保荐人（联席主承销商），中国国际金融股份有限公司 （以下简称"中金公司"）担任本次发行的联席主承销商。国泰海通、中金公司统 称联席主承销商。 敬请广大投资者关注。 发行人：北京屹唐半导体科技股份有限公司 保荐人（联席主承销商）：国泰海通证券股份有限公司 联席主承销商：中国国际金融股份有限公司 （此页无正文，为《北京屹唐半导体科技股份有限公司首次公开发行股票并 在科创板上市网上路演公告》盖章页） 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、 网下向符合条件的投资者询价配售（以下简称 ...

Core Viewpoint - The Shanghai Stock Exchange has decided to terminate the review of Qingdao Gulf Chemical Co., Ltd.'s initial public offering (IPO) and listing on the Shanghai Main Board due to the company's withdrawal of its application [1][3]. Group 1: Company Background - Qingdao Gulf Chemical's main business includes chlor-alkali chemicals, organic chemical raw materials, polymer new materials, and inorganic silicon products, with key products such as PVC, styrene, polystyrene, and caustic soda [3]. - The controlling shareholder of Gulf Chemical is Qingdao Gulf Group Co., Ltd., which holds 62% of the company's shares. The actual controller is the Qingdao State-owned Assets Supervision and Administration Commission through its ownership of Qingdao Investment [3]. Group 2: IPO Details - Gulf Chemical initially planned to issue no more than 25,344,990 shares, accounting for no more than 15% and no less than 10% of the total share capital after issuance [4]. - The company aimed to raise 300 million yuan for various projects, including a green circular economy project for epoxy chloropropane, an epoxy resin project, and an expansion project for ethylene oxychlorination [4][6]. - The total investment for the planned projects is approximately 460.69 million yuan, with specific allocations for each project detailed in the funding table [6].

股票简称：华之杰 股票代码：603400 苏州华之杰电讯股份有限公司 Suzhou Huazhijie Telecom Co., Ltd. （江苏省苏州市吴中区胥口镇孙武路 1031 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） （住所：北京市朝阳区安立路 66 号 4 号楼） 二〇二五年六月十九日 苏州华之杰电讯股份有限公司 上市公告书 特别提示 苏州华之杰电讯股份有限公司（以下简称"发行人"、"华之杰"、"本 公司"或"公司"）股票将于 2025 年 6 月 20 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 本上市公告书中若出现总数与各分项数值之和尾数不等的情况，均为四舍 五入尾差所致。 苏州华之杰电讯股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明与提示 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真 实、准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏， 并依法承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的 ...

山东信通电子股份有限公司 首次公开发行股票并在主板上市 网上路演公告 本次发行的招股意向书全文及相关资料可在中国证监会指定的网站（巨潮资 讯网，网址 www.cninfo.com.cn；中证网，网址 www.cs.com.cn；中国证券网，网 址 www.cnstock.com；证券时报网，网址 www.stcn.com；证券日报网，网址 www.zqrb.cn）查阅。 敬请广大投资者关注。 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、 网下向符合条件的投资者询价配售（以下简称"网下发行"）与网上向持有深圳市 场非限售 A 股股份和非限售存托凭证市值的社会公众投资者定价发行（以下简 称"网上发行"）相结合的方式进行。 发行人和保荐人（主承销商）招商证券股份有限公司（以下简称"保荐人（主 承销商）"或"招商证券"）将通过网下初步询价直接确定发行价格，网下不再进 行累计投标询价。 本次拟公开发行股票 3,900.00 万股，占发行后公司总股本的 25.00%，全部 为公开发行新股，公司股东不进行公开发售股份。 本次发行初始战略配售数量为 780.00 万股，占本次发行数量的 20.00%。 ...

影石创新科技股份有限公司 扫描二维码查阅公告全文 首次公开发行股票科创板 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 上市公告书提示性公告 保荐人（联席主承销商） ：中信证券股份有限公司 联席主承销商：高盛（中国）证券有限责任公司 联席主承销商：中国国际金融股份有限公司 （三）股票代码：688775 （四）本次发行后的总股本：401,000,000 股 （五）本次公开发行的股票数量：41,000,000 股，且占发行后总股本的比例 为 10.22%，本次发行不涉及老股转让 二、风险提示 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市初 期的投资风险，提醒广大投资者充分了解交易风险、理性参与新股交易，具体而 言，上市初期的风险包括但不限于以下几种： （一）涨跌幅限制放宽 根据《上海证券交易所交易规则》（2023 年修订），科创板股票交易实行价 格涨跌幅限制，涨跌幅限制比例为 20%。首次公开发行上市的股票上市后的前 5 个交易日不设价格涨跌幅限制。科创板股票存在股价波动幅度较剧烈的风险。 经上海证券交易所审核同意，影石创 ...

中国经济网北京6月5日讯科兴制药(688136.SH)昨晚发布股东减持股份计划公告。截至公告披露日，深 圳科益医药控股有限公司(以下简称"科益医药")直接持有科兴制药131,778,347股，占公司总股本的比例 为66.01%。科益医药直接持有的股份为其在公司首次公开发行前取得的股份，上述股份均已上市流 通。 科兴制药2020年以来3次分红合计派发现金红利5158.71万元。 科益医药本次拟通过集中竞价或大宗交易方式减持所持有的公司股份为不超过5,989,200股，即不超过公 司目前股份总数的3.00%。本次减持计划自公告披露之日起15个交易日后的3个月内(根据中国证券监督 管理委员会及上海证券交易所规定禁止减持的期间除外)进行。若减持计划实施期间公司发生送股、资 本公积金转增股本、配股等股份变动事项，将对拟减持股份数量和比例进行相应调整。 科兴制药2024年年度报告显示，深圳科益医药控股有限公司为公司控股股东，邓学勤为公司实际控制 人。 公司第二届董事会第二十二次会议审议通过《关于公司2024年度利润分配方案的议案》，公司2024年度 利润分配预案为：拟以实施权益分派股权登记日的总股本为基数，向全体股东按每 ...